-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target

Benzinga·06/11/2026 13:44:37
Listen to the news
Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $37 price target.